Michael Chen

INNOVATION COUNCIL MEMBER
Co-founder & Chief Scientific Officer, Seaport Therapeutics

Michael Chen, Ph.D., is Co-founder and Chief Scientific Officer of Seaport Therapeutics. In his most recent role, he was Head of Innovation at PureTech Health, where he oversaw the rapid advancement of the neuropsychiatric medicines that led to the launch of Seaport Therapeutics.

While spearheading PureTech’s overall efforts to generate and develop novel drug concepts, he also led the successful early development of LYT-100 (deupirfenidone) through proof-of-concept clinical studies. Dr. Chen was previously Co-founder and Head of Research and Strategy at Sonde Health. He was a postdoctoral fellow at Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Neurology. Dr. Chen completed his Ph.D. at Stanford University and Bachelor of Arts from Yale University.